SCHEMBL6490743

SCHEMBL6490743

Cc1ccc(C2=C(C(=O)Nc3ccc4c(c3)CCN4C(=O)Cc3ccccn3)CCCCCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF2AK3 Q9NZJ5 3/20 0.49
MAPT P10636 2/20 0.46
NPC1 O15118 2/20 0.46
TP53 P04637 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ADORA3 P0DMS8 1/20 0.42
ADORA2A P29274 1/20 0.42
NAMPT P43490 2/20 0.41
HTR2C P28335 7/20 0.41
HTR2B P41595 6/20 0.41
HTR2A P28223 5/20 0.41
POLB P06746 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
PDE7A Q13946 1/20 0.40
RIPK1 Q13546 1/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
SYK P43405 1/20 0.39
NFKB1 P19838 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490739 1.00 EIF2AK3 (0.49) EIF2AK3MAPTNPC1TP53RAB9A
SCHEMBL6499110 1.00 EIF2AK3 (0.49) EIF2AK3MAPTNPC1TP53RAB9A
SCHEMBL6491014 0.99 EIF2AK3 (0.50) EIF2AK3MAPTNPC1TP53RAB9A
SCHEMBL6500088 0.97 EIF2AK3 (0.50) EIF2AK3MAPTNPC1TP53RAB9A
SCHEMBL6498678 0.92 EIF2AK3 (0.49) EIF2AK3MAPTNPC1TP53RAB9A
SCHEMBL6500118 0.91 HTR2C (0.49) EIF2AK3MAPTRAB9ASMN1; SMN2HTR2C
SCHEMBL6489804 0.91 EIF2AK3 (0.48) EIF2AK3MAPTTP53RAB9ASMN1; SMN2
SCHEMBL6491599 0.90 EIF2AK3 (0.48) EIF2AK3MAPTNPC1TP53RAB9A
SCHEMBL6488689 0.90 EIF2AK3 (0.48) EIF2AK3MAPTTP53SMN1; SMN2HTR2C
SCHEMBL6489395 0.90 HTR2A (0.50) EIF2AK3HTR2CHTR2BHTR2ARIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 EIF2AK3 3626/4885MAPT 4202/4885NPC1 100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.